8-K: Calidi Biotherapeutics Reports Q1 2026 Results, Advances Pipeline

Calidi Biotherapeutics announced first quarter 2026 financial results, highlighting progress in its CLD-401 and RedTail platform development, alongside a significant reduction in administrative expenses.

Summary

• Calidi Biotherapeutics reported its first quarter 2026 financial results, showing a net loss of $4.4 million, or $0.43 per share, an improvement from the $5.0 million net loss, or $2.21 per share, in Q1 2025.
• The company presented new data on its CLD-401 candidate at the AACR conference, detailing its impact on the tumor microenvironment, with an IND filing anticipated by the end of 2026.
• Further advancements were showcased for the RedTail platform, including its use in creating in vivo T-cell engagers and data on CLD-501, a TROP-2 targeted agent.
• General and administrative expenses were reduced by $1 million year-over-year, from Q1 2025 to Q1 2026, attributed to decreased headcount, consulting, and rent.
• Calidi also announced a strategic partnership with TransferAI to enhance the IND submission process for CLD-401 using AI technology.
• The company had approximately $6.6 million in cash as of March 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with clear progress in pipeline development and operational efficiency, though the company continues to operate at a net loss and faces inherent risks in drug development.

Positives

• Reduced net loss attributable to common stockholders to $4.4 million in Q1 2026 from $5.0 million in Q1 2025.
• Reduced general and administrative expenses by $1 million from Q1 2025 to Q1 2026.
• Presented promising preclinical data for CLD-401 at the AACR conference, indicating profound immune changes in the tumor microenvironment.
• Advanced the RedTail platform with new data on in vivo T-cell engagers and CLD-501.
• Entered a strategic partnership with TransferAI to streamline the IND submission process for CLD-401.
• Increased cash balance to $6.6 million as of March 31, 2026, from $5.6 million as of December 31, 2025.

Negatives

• Reported a net loss of $4.4 million for the first quarter of 2026.
• Research and development expenses increased to $2.6 million in Q1 2026 from $2.4 million in Q1 2025.
• The company's net loss per share remains significant at $0.43 for Q1 2026.

Risks

• The risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• The risk that early results of clinical trials do not necessarily predict final results and that one or more clinical outcomes may materially change.
• The risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Risks related to the timing, cost, and results of research and development activities and preclinical studies.
• Risks associated with interactions with and feedback from regulatory authorities.
• Risks related to manufacturing and supply chain matters.
• Risks associated with the availability of capital and other resources.
• Risks related to changes in business, market, economic, or competitive conditions.

Future Outlook

The company anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026. The RedTail platform continues to be advanced for various therapeutic applications, including in situ T-cell engagers.

Management Comments

• "We are excited about the continued progress at Calidi," said Eric Poma, PhD, Calidi Biotherapeutics CEO.
• "We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts."
• "We have also expanded what the RedTail platform can do with our new approach of in situ T-cell engagers."

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics is operating in the highly competitive and rapidly evolving oncology and gene therapy sector. The company's focus on oncolytic viruses and targeted genetic medicines aligns with broader industry trends aiming for more precise and effective cancer treatments. The advancement of their RedTail platform and specific candidates like CLD-401 positions them among other biotech firms seeking to overcome challenges in systemic drug delivery and immune evasion.

Comparison to Industry Standards

• The reduction in G&A expenses by $1 million demonstrates a focus on operational efficiency, which is a key benchmark for early-stage biotech companies managing burn rates.
• The net loss per share of $0.43, while significant, shows an improvement compared to the prior year's $2.21, indicating progress in managing financial performance relative to development stage.
• The cash balance of $6.6 million provides a runway for continued R&D, but is modest compared to larger, more established biopharmaceutical companies, highlighting the need for future capital raises.

Related Party Transactions

• Related party accounts payable of $51,000 as of March 31, 2026.
• Related party accrued expenses and other current liabilities of $119,000 as of March 31, 2026.
• Related party warrant liability of $5,000 as of March 31, 2026.
• Interest expense related party of $5,000 for the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders: Improved net loss per share and cash position are positive, but continued losses and the need for future capital may impact share value.
• Employees: A $1 million reduction in G&A expenses may have implications for headcount or operational support.
• Creditors: The company's cash position and ongoing losses will be a consideration for creditors.

Next Steps

• Submit IND application for CLD-401 by the end of 2026.
• Continue advancing the RedTail platform and its applications, including in situ T-cell engagers.
• Leverage the strategic partnership with TransferAI to drive efficiencies in the IND submission process.

Key Dates

Recommendation

The company shows promising pipeline progress and operational improvements, but the significant net loss, ongoing R&D investment, and inherent risks in drug development warrant a cautious 'hold' recommendation. Investors should monitor future IND progress and capital raise activities.

Keywords

Calidi Biotherapeutics, CLD-401, RedTail platform, oncology, biotechnology, clinical trials, IND filing, T-cell engagers